Hall T J, Higgins W, Tardif C, Chambers T J
Merrell Dow Research Institute, Strasbourg, France.
Calcif Tissue Int. 1991 Nov;49(5):328-32. doi: 10.1007/BF02556255.
We have assessed the effects of five sulfonamides with widely varying inhibitory activity for carbonic anhydrase (CA) in the bone slice assay using disaggregated rat osteoclasts (OCs), and in the Maren assay where the catalytic activity of purified CA isozyme II (CA II) was measured. There was an excellent correlation between the relative potencies of the compounds in the two assays: ethoxzolamide (ETH) greater than acetazolamide (AZ) greater than M&B 21659 greater than M&B 9811 greater than M&B 7973. In the bone slice assay, ETH and AZ were found to be the most potent inhibitors of OC bone resorption, with IC50 values of 0.09 and 0.8 microM, respectively (from plan surface area of bone resorbed). These results support previous observations showing that OCs use CA II to generate protons during bone resorption and that CA II activity is essential for OCs to be able to resorb bone.
我们使用分离的大鼠破骨细胞(OCs),在骨切片试验中评估了五种对碳酸酐酶(CA)具有广泛不同抑制活性的磺胺类药物的作用,并在测量纯化的CA同工酶II(CA II)催化活性的马伦试验中进行了评估。在这两种试验中,化合物的相对效力之间存在极好的相关性:乙氧唑胺(ETH)大于乙酰唑胺(AZ)大于M&B 21659大于M&B 9811大于M&B 7973。在骨切片试验中,发现ETH和AZ是OC骨吸收的最有效抑制剂,IC50值分别为0.09和0.8 microM(基于骨吸收的平面表面积)。这些结果支持了先前的观察结果,即OCs在骨吸收过程中利用CA II产生质子,并且CA II活性对于OCs能够吸收骨至关重要。